News

Per updated guidance for its upcoming 2024 fiscal year, issued on Dec. 13, Pfizer (NYSE: PFE) has a bumpy road ahead -- at least for now. Amidst rapidly weakening coronavirus product revenue and

Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and

Many investors will likely be wearing big smiles as 2023 winds down. The S&P 500 is on track to deliver a gain of over 20% and could hit an all-time high. The Nasdaq-100 has soared more than 50% and

The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

This year hasn't been kind to biotech stocks, which as a group haven't kept pace with the broader market. The performance of the SPDR S&P Biotech ETF makes that clear. Leading drugmaker Amgen

Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on

Earlier in the pandemic, Pfizer (NYSE: PFE) stood out as an earnings and stock-market star thanks to its leading coronavirus vaccine and treatment. But these days, those products are weighing on

On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light

On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light

On Dec. 8, CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals (NASDAQ: VRTX) made history when the Food and Drug Administration (FDA) gave them the green light

Having at least $1 million in the bank by retirement has long been a popular goal, but it isn't easy to accomplish. One of the best ways to do so is to invest in stocks, and the earlier one starts

Having at least $1 million in the bank by retirement has long been a popular goal, but it isn't easy to accomplish. One of the best ways to do so is to invest in stocks, and the earlier one starts

You might think that the stock market would be really quiet during the holidays. After all, many investors are on vacation and take a break from buying and selling stocks. Interestingly, though, the

It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in

It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in

It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over